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We appreciated the Comment Letter from the Austrian
colleagues referring to the recently published Consensus
Statement on clinical definition of refractory Chronic
Migraine (rCM), authored by the European Headache
Federation (EHF) Expert Group [1,2].
In this Comment Letter [3] the authors present Chron-
ische Migrane: Therapie, Therapieresistenz und Neuromo-
dulation – Ein Konsensus-Statement, a consensus statement
on CM with and without medication overuse, therapeutic
options, with particular focus on patients selection for
Occipital Nerve Stimulation (ONS). This article was
published in a non-indexed national journal, supported
by the device manufacturer [4].
We would like to underline the structural difference
existing between the EHF paper and the Austrian one:
the first one is finalized to the clinical definition of rCM
and the proposal of criteria to be evaluated for a future
inclusion of rCM as 3-digit diagnosis of CM in the next
ICHD-3 (1.3.1 Refractory Chronic Migraine). The latter
mostly targets to patients selection for ONS: “Diagnostic
criteria for rCM and guidelines for managing targets pa-
tients with rCM and selecting candidates for invasive
neuromodulation are crucial issues [4]”. In contrast, the
EHF Consensus clearly states “The European Headache
Federation felt to develop new consensus criteria that de-
fine rCM, particularly for the purposes of controlled
clinical trials that involve experimental medication and
neuromodulation independently from the non-invasive
therapies or the implantable devices [1,5]”.
In particular four points should be addressed:
1. The Notified Body has just removed the CE mark
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in any medium, provided the original work is prCM patients [6]. Therefore, any speculation on the
definition of rCM criteria useful for ONS selection
[4,7] falls exclusively on future randomized controlled
trials (RCTs).
2. The semantic debate on EHF criteria “requiring at
least 3 different drugs from the following classes” [4]
is a misinterpretation of our words: “at least 3 drugs
from the following classes” (clearly shown on Table
two in our publication) contains 5 classes, 4 of which
do not reach 3 items [1]. This fact clearly shows the
inconsistency of this criticism. Furthermore, the
observation on the minimum dose of prophylactic
drugs used is not at all useful in a contest of a
definition of refractoriness.
3. The EHF proposed criteria for rCM are defined
“inconsistent with respect to MO, since criterion A
requires no MO, but recommendations for
detoxification are given in the notes”. We think that
the wide acceptance of any kind of detoxification
procedure guarantees ICHD-3 beta CM diagnosis an
uncomplicated purity from acute drugs abuse that
might be a confusing factor in the given criteria.
4. The criticism about “laboratory and CSF analyses
within the normal range, including CSF pressure”,
as reported in the notes at Table two of the EHF
Statement, should be seen as a wide evaluation
opportunity of many forms of secondary headaches
without decontextualize the phrase deleting the
term “laboratory”.
We thank the authors of the letter for taking the time to
comment our paper, yet this falls partially into our pur-
poses to initiate a European and worldwide discussion on
the refractoriness of primary headache disorders, coagulat-
ing the various emerging attempts [8].is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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